Hybrigenics Starts Phase II Clinical Trial of Inecalcitol in Chronic Lymphocytic Leukemia
9/11/2012 11:00:28 AM
More...
|
Bryan, Garnier & Co Initiates Coverage of Hybrigenics with a Target Price of €2.6
3/29/2012 6:56:24 AM
More...
|
Hybrigenics' Specific Inhibitor of Ubiquitin-Specific Protease 7 (USP7) is Cytotoxic for Chronic Lymphocytic Leukaemia (CLL) Cells in Vitro
10/28/2011 10:33:53 AM
More...
|
Hybrigenics 2011 First-Half Results
10/18/2011 11:02:59 AM
More...
|
Hybrigenics and Servier Enter into a License and Research Collaboration Agreement in Oncology and Other Therapeutic Fields
10/10/2011 9:49:14 AM
More...
|
Hybrigenics Appoints Dr Alain Munoz to its Board of Directors
10/5/2011 10:55:57 AM
More...
|
Hybrigenics Gets Approval and Funding for a Phase II Clinical Trial of Inecalcitol in Psoriasis
9/6/2011 11:27:12 AM
More...
|
Hybrigenics Maintains Stable EUR Two Million Revenues in First Half of 2011
8/23/2011 10:00:15 AM
More...
|
Hybrigenics' Inecalcitol Inhibits the Growth of Human Hormone-Dependent Prostate Cancer Cells in Vitro and in Vivo
7/12/2011 9:23:23 AM
More...
|
Hybrigenics to Present Inecalcitol Results at the Annual Meeting of the American Society of Clinical Oncology
6/1/2011 8:46:52 AM
More...
|
|